Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T‐cell lymphoma with analysis of biomarkers

Peripheral T‐cell lymphoma (PTCL) has a poorer prognosis than diffuse large B‐cell lymphoma (DLBCL). We administered the CyclOBEAP regimen (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) to patients with DLBCL, and reported its safety and efficacy. Here, we report the results of a multicentre phase II study of the CyclOBEAP regimen in patients with PTCL. In addition, NME1 remained a prognostic factor for survival, as shown in patients who were treated with CyclOBEAP. There were 84 eligible patients and the median age was 54 years. The 5‐year overall survival (OS) rate was 72% and progression‐free survival (PFS) rate was 61%. The 5‐year OS was 93% among the anaplastic large‐cell lymphoma cases, 74% among the angioimmunoblastic T‐cell lymphoma cases, and 63% among the cases of PTCL‐not otherwise specified. When the patients were divided according to the International Prognostic Index or Prognostic Index for PTCL, the 5‐year OS and PFS rates did not significantly differ among the risk groups. Positivity for NME1 was found to be a significant independent prognostic factor. Grade 4 neutropenia was observed in 80 patients and thrombocytopenia in nine patients. Our results suggest that the CyclOBEAP therapy is safe and effective for PTCLs. Furthermore, the NME1 protein may be an important prognostic factor in PTCL.

[1]  J. Rossi,et al.  Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95 , 2010, British journal of haematology.

[2]  N. Niitsu,et al.  Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B‐cell lymphoma , 2010, Hematological oncology.

[3]  H. Nakamine,et al.  A clinicopathological study of nm23-H1 expression in classical Hodgkin's lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Nakamine,et al.  Clinico‐pathologic features and outcome of Japanese patients with peripheral T‐cell lymphomas , 2008, Hematological oncology.

[6]  P. Gaulard,et al.  Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. , 2008, Blood.

[7]  J. Rodríguez,et al.  Frontline autologous stem cell transplantation in high‐risk peripheral T‐cell lymphoma: a prospective study from The Gel‐Tamo Study Group , 2007, European journal of haematology.

[8]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Gaulard,et al.  Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. , 2006, Blood.

[10]  T. Yoshino,et al.  Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma , 2006, Annals of Hematology.

[11]  Y. Kagami,et al.  Clinicopathologic and Prognostic Significance of Cytotoxic Molecule Expression in Nodal Peripheral T-Cell Lymphoma, Unspecified , 2005, The American journal of surgical pathology.

[12]  Terry L. Smith,et al.  Prognostic factors and treatment of patients with T‐cell non‐Hodgkin lymphoma , 2005, Cancer.

[13]  T. Miyazaki,et al.  Long-term Results of a Multicenter Randomized, Comparative Trial of Modified CHOP versus THP-COP versus THP-COPE Regimens in Elderly Patients with Non-Hodgkin’s Lymphoma , 2005, International journal of hematology.

[14]  Dirk Hasenclever,et al.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. , 2004, Blood.

[15]  H. Nakamine,et al.  Clinical Significance of Intracytoplasmic nm23-H1 Expression in Diffuse Large B-Cell Lymphoma , 2004, Clinical Cancer Research.

[16]  T. Molina,et al.  Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. , 2003, Blood.

[17]  B. Nathwani,et al.  Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Y. Honma,et al.  Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. , 2001, Blood.

[19]  P. Gaulard,et al.  Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.

[20]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[21]  J E Talmadge,et al.  Evidence for a novel gene associated with low tumor metastatic potential. , 1988, Journal of the National Cancer Institute.

[22]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[23]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[24]  F. Wilcoxon.  Individual Comparisons by Ranking Methods , 1945 .

[25]  N. Schmitz,et al.  Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  K. Savage.  Prognosis and primary therapy in peripheral T-cell lymphomas. , 2008, Hematology. American Society of Hematology. Education Program.

[27]  D.,et al.  Regression Models and Life-Tables , 2022 .